相关实验视频

Updated: May 5, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

微质激活在临床前阿尔茨海默病中增加,并与隐性记忆障碍相关

Pernille Louise Kjeldsen^1,2,3, Lasse Stensvig Madsen^1,3, Peter Parbo^1,4

¹Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Frontiers in dementia

|February 12, 2026

概括

微质激活在临床前阿尔茨海默氏症 (AD) 中升高,并与记忆力下降有关. 这表明神经炎症在认知症状出现之前,在早期AD病变发生中起作用.

科学领域:

神经科学是一个神经科学.
神经学神经学
免疫学免疫学免疫学

背景情况:

阿尔茨海默氏病 (AD) 进展到临床前阶段,出现疾病,但没有明显的症状.
关键的AD病理包括β-粉样蛋白 (Aβ) 斑块和神经纤维状,Aβ沉积发生在早期.
微质激活与阿尔茨海默病有关,但其在临床前阶段的确切时间和作用尚不清楚.

研究的目的:

调查在临床前AD中微质激活的流行率.
检查在临床前AD中微质激活,Aβ沉积和记忆功能之间的关联.

主要方法:

使用11C-匹兹堡化合物B (11C-PiB) PET来识别具有异常Aβ沉积的临床前阿尔茨海默病患者.
使用11C-PK11195PET测量在临床前AD患者和健康对照中的微质激活.
进行敏感的记忆测试,以评估临床前阿尔茨海默病患者的认知功能.

主要成果:

在临床前的阿尔茨海默病患者显示,与对照人群相比,尾和尾皮层的微质激活显著更高.
在表层区域的Aβ负载和微质激活之间观察到显著的正相关性.
微质激活与特定皮质区域的记忆测试表现有负相关.

结论:

在临床前阿尔茨海默氏症患者中,即使没有认知投诉,微质活化也会升高.
增加的微质激活与AD临床前阶段的记忆障碍有关.
这些发现表明,微质激活可能会在阿尔茨海默病发病的早期对认知产生不利影响.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在这里,PET是PET.氨基化物氨基化物认知认知认知记忆记忆记忆记忆记忆微质细胞中的微质细胞

更多相关视频

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

Published on: May 11, 2015

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...